Skip to main content
Day.News — Local News. Real Community.
COLUMBUS DAY NEWS
Local News. Real Community.
health
1 min read

CDC Reports First U.S. Cases of Emerging Fungal Infection, Candida auris

The Centers for Disease Control and Prevention (CDC) has reported the first thirteen cases of Candida auris (C. auris) in the United States. C. auris is a fungal infection that has emerged globally and is sometimes fatal.

04/30/2026 · Alabama edition

Advertisement

Advertisement

The Centers for Disease Control and Prevention (CDC) has confirmed the identification of thirteen cases of the fungal infection Candida auris, also known as C. auris, within the United States.

Candida auris is an emerging fungal pathogen that has garnered international attention due to its resistance to multiple antifungal medications. The CDC is monitoring the situation to understand the scope of the outbreak, modes of transmission, and impact on vulnerable populations.

Specific details regarding the location of the identified cases were not provided in the initial CDC announcement. Further updates are expected as the CDC and state health departments continue to investigate the occurrences.

Related Topics

Editorial Transparency
AI-Generated · Written by National Desk

Article Ratings

Factual
0.0
Likeable
0.0
Bias
0.0
Objective
0.0

How do you feel about this story?

NA

National Desk

Trust 3.1103384 articles8,231,170 views75% fact accuracy
View Profile

Sign in to follow this author from their profile.

Discussion (0)

Join the Conversation

Join the conversation

Sign in to share your thoughts, reply to readers, and like comments.

Sign in to comment
Sort by:
0 comments

No comments yet. Be the first to comment!

Trending Now

Trending stories will appear here.

More from Alabama

No other local stories are available right now.

Events & Things to Do

Read section →

Upcoming events will appear here.

Advertisement

Advertisement

Keep Reading

Related Stories

More health stories from Alabama

health

FDA to Conclude Abortion Pill Safety Review by March

The Food and Drug Administration (FDA) will finalize its safety review of mifepristone in March. A Louisiana federal judge mandated this update as part of a legal challenge seeking to reverse a policy allowing mail delivery of the abortion medication.

Read Story →
health

GLP-1 Medications Show Potential in Addressing Addiction

New evidence suggests GLP-1 drugs, commonly used for diabetes and weight loss, may also reduce cravings for addictive substances. Scientists are conducting studies to determine if these medications can help individuals with substance use disorders. This research explores a potential new application for GLP-1s in public health.

Read Story →
health

Report Examines Impact of Trump Administration's Drug Pricing Initiatives

A recent report evaluated the Trump administration's claims regarding drug prices, including the effectiveness of TrumpRx discounts. Findings indicate a mixed impact on prescription drug costs for consumers. The administration has asserted that the U.S. now pays the world's lowest drug prices.

Read Story →
health

Cost of GLP-1 Medications Prompts Search for Alternatives

Many Americans face financial hurdles when trying to access GLP-1 medications. These cost barriers have prompted some patients to seek out alternative, unregulated versions. The situation highlights ongoing challenges in prescription drug affordability.

Read Story →
health

Experimental Vaccine Shows Promise Against Glioblastoma

An experimental vaccine for glioblastoma, a severe form of brain cancer, demonstrates potential to prolong life for patients. Developers report encouraging results from ongoing studies.

Read Story →
health

Medicare for All Becomes Midterm Campaign Focus Amid Voter Support

Candidates in midterm elections are increasingly discussing 'Medicare for All.' A recent poll shows two-thirds of Americans support the concept. This reflects a public desire for significant changes in health care.

Read Story →
Scroll for more stories